Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.5.2003

Alpha-fetoprotein (AFP) Elevation Gastric Adenocarcinoma and Importance of AFP Change in Tumor Response Evaluation  

Tatli, Ali Murat (Department Oncology Medical, Van Training and Research Hospital)
Urakci, Zuhat (Department Oncology Medical, Dicle University, Medical Faculty)
Kalender, Mehmet Emin (Department Oncology Medical, Gaziantep University, Medical Faculty)
Arslan, Harun (Department Radiology, Van Training and Research Hospital)
Tastekin, Didem (Department Oncology Medical, IstanbulUniversity, Medical Faculty)
Kaplan, Mehmet Ali (Department Oncology Medical, Dicle University, Medical Faculty)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.5, 2015 , pp. 2003-2007 More about this Journal
Abstract
Background: Elevated serum alpha-fetoprotein (AFP) levels in adults are considered abnormal. This parameter is used mostly in the diagnosis and follow-up of hepatocellular carcinomas and yolk sac tumors. Among the other rare tumors accompanied with elevated serum AFP levels, gastric cancer is the most common. In this study, we evaluated the follow-up and comparison of the treatment and marker response of patients with metastatic gastric cancer who had elevated serum AFP levels. Materials and Methods: We performed a retrospective study, including all consecutive patients with advanced gastric cancer, who received systemic chemotherapy with elevated AFP level. Results: Seventeen metastatic gastric cancer patients with elevated AFP levels at the time of diagnosis were evaluated. Fourteen (82.4%) were males and three (17.6%) were females. The primary tumor localization was the gastric body in 8 (76.4%), cardia in 7 (41.2%), and antrum in 2 (11.8%). Hepatic metastasis was observed in 13 (76.4%) at the time of diagnosis. When the relationship of AFP levels and carcinoembryonic antigen (CEA) response of the patients with their radiologic responses was evaluated, it was found that the radiologic response was compatible with AFP response in 16 (94.1%) patients and with CEA response in 12 (70.6%); however, in 5 (29.4%) patients no accordance was observed between radiological and CEA responses. Conclusions: Follow-up of AFP levels in metastatic gastric cancer patients with elevated AFP levels may allow prediction of early treatment response and could be more useful than the CEA marker for follow-up in response evaluation.
Keywords
Alpha-fetoprotein; chemotherapy; gastric cancer; CEA;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Akai S, Kato K (1973). Serum ${\alpha}$-fetoprotein-positive stomach cancer. Gann Monogr, 14, 149-54.
2 Baek SK, Han SW, Oh DY, et al (2011). Clinic pathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer. BMC Gastroenterol, 11, 1-7.   DOI
3 Bourreille J, Metayer P, Sauger F, et al (1970). Existence of alpha feto protein during gastric-origin secondary cancer of the liver. Presse Med, 78, 1277-8.
4 Chang YC, Nagasue N, Abe S, et al (1990). The characteristics of AFP-producing early gastric cancer. J Jpn Surg Soc, 91, 1574-80.
5 Chang YC, Nagasue N, Abe S, et al (1992). Comparison between the clinicopathologic features of AFP-positive and AFPnegative gastric cancers. Am J Gastroenterol, 87, 321-5.
6 Chun H, Kwon SJ (2011). Clinic pathological characteristics of alpha-fetoprotein-producing gastric cancer. J Gastric Cancer, 11, 23-30.   DOI   ScienceOn
7 Gitlin D, Pericelli A, Gitlin GM (1972). Synthesis of-fetoprotein by liver, yolk sac, and gastrointestinal tract of the human conceptus. Cancer Res, 32, 979-82.
8 Hamanaka W, Yoneda S, Shirakusa T, et al (2008). Alphafetoprotein (AFP)-producing adrenocortical carcinoma-long survival with various therapeutic strategies including a lung resection: Report of a case. Surg Today, 38, 275-8.   DOI
9 Hocking GR, Shembrey M, Hay D, et al (1995). Alphafetoprotein- producing adenocarcinoma of the sigmoid colon with possible hepatoid differentiation. Pathology, 27, 277-9.   DOI
10 Inoue M, Sano T, Kuchiba A, et al (2008). Long-term results of gastrectomy for $\alpha$-fetoprotein-producing gastric cancer. Br J Surg, 97, 1056-61.
11 Isonishi S, Ogura A, Kiyokawa T, et al (2009). Alpha-fetoprotein (AFP)- producing ovarian tumor in an elderly woman. Int J Clin Oncol, 14, 70-3.   DOI
12 Lin HJ, Hsieh Y.H, Fang WL, et al (2014). Clinical manifestations in patients with alpha-fetoprotein-producing gastric cancer. Curr Oncol, 21, 394-9.   DOI
13 Liu X, Cheng Y, Sheng W, et al (2010). Analysis of clinicopathologic features and prognostic factors in hepatoid adenocarcinoma of the stomach. Am J SurgPathol, 34, 1465-71.
14 McIntire KR, Waldmann TA, Moertel CG, et al (1971). Serum alpha-fetoprotein in patients with neoplastic carcinomas. N Engl J Med, 285, 1060-1.   DOI
15 Liu X, Cheng Y, Sheng W, et al (2010). Clinicopathologic features and prognostic factors in alpha-fetoproteinproducing gastric cancers: analysis of 104 cases. J Surg Oncol, 102, 249-55.   DOI
16 Maruyama K, Kaminishi M, Hayashi K, et al (2006). Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer, 9, 51-66.   DOI
17 Marx GM, Boyce A, Goldstein D (2002). Elevated $\alpha$-fetoprotein and hepatic metastases-it's not always what it seems! Ann Oncol, 13, 167-9.
18 Mittal A, Gupta SP, Jha DK, et al (2013). Impact of various tumor markers in prognosis of gastric cancer. a hospital based study from tertiary care hospital of Kathmandu valley. Asian Pac J Cancer Prev, 14, 1965-7.   DOI   ScienceOn
19 Motoyama T, Aizawa K, Watanabe H, et al (1993). Alphafetoprotein- producing gastric carcinomas: A comparative study of three different subtypes. Acta Pathol Jpn, 43, 654-61.
20 Nagai E, Ueyama T, Yao T, et al (1993). Hepatoid adenocarcinoma of the stomach. Cancer, 72, 1827-35.   DOI
21 Riaz A, Ryu RK, Kulik LM, et al (2009). Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol, 27, 5734-42.   DOI
22 Saito S, Hatano T, Hayakawa M, et al (1989). Studies on alphafetoprotein produced by renal cell carcinoma. Cancer, 63, 544-9.   DOI
23 Trompetas V, Varsamidakis N, Frangia K, et al (2003). Gastric hepatoid adenocarcinoma and familial investigation: does it always produce alpha-fetoprotein? Eur J Gastroenterol Hepatol, 15, 1241-4.   DOI
24 Shibata Y, Sato K, Kodama M, et al (2007). Alpha-fetoproteinproducing early gastric cancer of the remnant stomach: Report of a case. Surg Today, 37, 995-9.   DOI
25 Shu J, Li CG, Liu YC, et al (2012). Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients. Asian Pac J Cancer Prev, 13, 2399-403.   DOI
26 Takahashi Y, Mai O, Ogino T, et al (1987). Clinicopathological study of AFP-producing gastric cancer. Significance of AFP in gastric cancer. J Jpn Surg Soc, 88, 696-700.
27 Turkdogan MK, Akman N, Tuncer I, et al (1998). The high prevalence of esophageal and gastric cancers in Eastern Turkey. Med Biol Environ, 26, 79-84.
28 Turkdogan MK, Testereci H, Akman N, et al (2003). Dietary nitrate and nitrite levels in an endemic upper gastrointestinal (esophageal and gastric) cancer region of Turkey. Turk J Gastroenterol, 14, 50-3.
29 Ueno M, Nakashima J, Ohigashi T, et al (2001). Establishment of a testicular carcinoma cell line producing alpha-fetoprotein. BJU Int, 88, 611-21.
30 Yamagata T, Yamagata Y, Nakanishi M, et al (2004). A case of primary lung cancer producing alpha-fetoprotein. Can Respir J, 11, 504-6.   DOI
31 Yamao T, Kai S, Kazami A, et al (1999). Tumor markers CEA, CA19-9 and CA125in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol, 29, 550-5.   DOI
32 Zhang JF, Shi SS, Shao YF, et al (2011). Clinic pathological and prognostic features of hepatoid adenocarcinoma of the stomach. Chin Med J, 124, 1470-6.